Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment.

…read more

Source: Catalyst soars as its controversial rare disease drug aces Phase III